Terms: = Sarcomas AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
429 results:
1. Radiotherapy combined with anti-pd-1 and TKI for primary cardiac angiosarcoma considering the joint assessment of TLSs and PD-L1: a case report.
Deng S; Yang X; He L; Zhang Q; Zhao C; Meng H
J Cardiothorac Surg; 2024 Apr; 19(1):194. PubMed ID: 38594687
[TBL] [Abstract] [Full Text] [Related]
2. Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.
Liao Z; Teng J; Li T; Liu H; Li T; Zhang C; Xing R; Teng S; Yang Y; Zhao J; Xiao W; Zhang G; Li MJ; Yao W; Yang J
Front Immunol; 2024; 15():1292325. PubMed ID: 38585276
[TBL] [Abstract] [Full Text] [Related]
3. A synergistic approach for modulating the tumor microenvironment to enhance nano-immunotherapy in sarcomas.
Mpekris F; Panagi M; Charalambous A; Voutouri C; Michael C; Papoui A; Stylianopoulos T
Neoplasia; 2024 May; 51():100990. PubMed ID: 38520790
[TBL] [Abstract] [Full Text] [Related]
4. The Development and Characterization of a Next-Generation Oncolytic Virus Armed with an Anti-pd-1 sdAb for Osteosarcoma Treatment
Higgins TA; Patton DJ; Shimko-Lofano IM; Eller TL; Molinari R; Sandey M; Ismail A; Smith BF; Agarwal P
Cells; 2024 Feb; 13(4):. PubMed ID: 38391964
[TBL] [Abstract] [Full Text] [Related]
5. Immunohistochemistry assessment of tissue neutrophil-to-lymphocyte ratio predicts outcomes in melanoma patients treated with anti-programmed cell death 1 therapy.
Teixeira RJ; de Souza VG; Sorroche BP; Paes VG; Zambuzi-Roberto FA; Pereira CAD; Vazquez VL; Arantes LMRB
Melanoma Res; 2024 Jun; 34(3):234-240. PubMed ID: 38364053
[TBL] [Abstract] [Full Text] [Related]
6. Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-pd1-resistant cancer patients.
Tan Q; Gao R; Zhang X; Yang J; Xing P; Yang S; Wang D; Wang G; Wang S; Yao J; Zhang Z; Tang L; Yu X; Han X; Shi Y
Cancer Immunol Immunother; 2024 Feb; 73(3):47. PubMed ID: 38349411
[TBL] [Abstract] [Full Text] [Related]
7. Network pharmacology and experimental validation to study the potential mechanism of Tongguanteng injection in regulating apoptosis in osteosarcoma.
Wei L; Meng J; Xiang D; Yang Q; Zhou Y; Xu L; Wang M; Chen J; Han Y
BMC Complement Med Ther; 2024 Jan; 24(1):67. PubMed ID: 38297292
[TBL] [Abstract] [Full Text] [Related]
8. Unraveling T cell exhaustion in the immune microenvironment of osteosarcoma via single-cell RNA transcriptome.
Cheng D; Zhang Z; Liu D; Mi Z; Tao W; Fu J; Fan H
Cancer Immunol Immunother; 2024 Jan; 73(2):35. PubMed ID: 38280005
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant pd-1 based immunotherapy.
Taylor AM; McKeown J; Dimitriou F; Jacques SK; Zimmer L; Allayous C; Yeoh HL; Haydon A; Ressler JM; Galea C; Woodford R; Kahler K; Hauschild A; Festino L; Hoeller C; Schwarze JK; Neyns B; Wicky A; Michielin O; Placzke J; Rutkowski P; Johnson DB; Lebbe C; Dummer R; Ascierto PA; Lo S; Long GV; Carlino MS; Menzies AM
Eur J Cancer; 2024 Mar; 199():113561. PubMed ID: 38278009
[TBL] [Abstract] [Full Text] [Related]
10. Immune characteristics of dedifferentiated retroperitoneal liposarcomas and the reliability of regional samples in evaluating their tumor immune microenvironments.
Zhou C; Li M; Ren Y; Miao F; Wang Y; Wu T; Gou X; Li W
World J Surg Oncol; 2024 Jan; 22(1):25. PubMed ID: 38254190
[TBL] [Abstract] [Full Text] [Related]
11. Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue sarcomas: Clinical Outcomes and Biological Correlates.
Haddox CL; Nathenson MJ; Mazzola E; Lin JR; Baginska J; Nau A; Weirather JL; Choy E; Marino-Enriquez A; Morgan JA; Cote GM; Merriam P; Wagner AJ; Sorger PK; Santagata S; George S
Clin Cancer Res; 2024 Apr; 30(7):1281-1292. PubMed ID: 38236580
[TBL] [Abstract] [Full Text] [Related]
12. Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-pd-1 treatment.
Baginska J; Nau A; Gomez Diaz I; Giobbie-Hurder A; Weirather J; Vergara J; Abrecht C; Hallisey M; Dennis J; Severgnini M; Huezo J; Marciello I; Rahma O; Manos M; Brohl AS; Bedard PL; Renouf DJ; Sharon E; Streicher H; Ott PA; Buchbinder EI; Hodi FS
Cancer Immunol Immunother; 2024 Jan; 73(1):17. PubMed ID: 38236249
[TBL] [Abstract] [Full Text] [Related]
13. Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers.
Jin Y; Dunn C; Persiconi I; Sike A; Skorstad G; Beck C; Kyte JA
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203757
[TBL] [Abstract] [Full Text] [Related]
14. Single agent vs combination immunotherapy in advanced melanoma: a review of the evidence.
Benhima N; Belbaraka R; Langouo Fontsa MD
Curr Opin Oncol; 2024 Mar; 36(2):69-73. PubMed ID: 38193381
[TBL] [Abstract] [Full Text] [Related]
15. Clinical and therapeutical significances of the cluster and signature based on oxidative stress for osteosarcoma.
Ding M; Ran X; Qian S; Zhang Y; Wang Z; Dong M; Yang Z; Wu S; Feng X; Zhang J; Zhu L; Niu S; Zhang X
Aging (Albany NY); 2023 Dec; 15(24):15360-15381. PubMed ID: 38180104
[TBL] [Abstract] [Full Text] [Related]
16. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
[TBL] [Abstract] [Full Text] [Related]
17. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
Ascierto PA; Casula M; Bulgarelli J; Pisano M; Piccinini C; Piccin L; Cossu A; Mandalà M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance A; Guida M; Maiello E; Gogas H; Richtig E; Fierro MT; Lebbe C; Helgadottir H; Queirolo P; Spagnolo F; Tucci M; Del Vecchio M; Cao MG; Minisini AM; De Placido S; Sanmamed MF; Mallardo D; Paone M; Vitale MG; Melero I; Grimaldi AM; Giannarelli D; Dummer R; Sileni VC; Palmieri G
Nat Commun; 2024 Jan; 15(1):146. PubMed ID: 38167503
[TBL] [Abstract] [Full Text] [Related]
18. Sarcoma in patients with Lynch syndrome and response to immunotherapy.
Shehata MS; Lofftus SY; Park JY; Singh AS; Federman NC; Eilber FC; Crompton JG; McCaw TR
J Surg Oncol; 2024 Mar; 129(4):820-826. PubMed ID: 38151827
[TBL] [Abstract] [Full Text] [Related]
19. A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas.
Zhou Y; Li M; Zhang B; Yang C; Wang Y; Zheng S; Tang L; Zhou C; Qian G; Huang Y; Yu W; Li H; Wang Y; He A; Shen Z; Zhang J; Li X; Yang Q; Hu H; Yao Y
BMC Med; 2023 Nov; 21(1):470. PubMed ID: 38031088
[TBL] [Abstract] [Full Text] [Related]
20. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
[Next]